[Comorbid anxiety disorders in patients with neurological pathology: current state of the problem and the role of etifoxine in treatment strategy].

The article presents theses of the resolution of the Interdisciplinary Council of Experts in Psychiatry and Neurology (Moscow, 2024) on the issue of comorbid anxiety disorders (AD) in patients with neurological pathologies. The authors highlight the high prevalence of comorbid ADs and their significant negative impact on the course of underlying diseases, such as epilepsy, pain syndromes and post-stroke conditions. Modern approaches to the diagnosis and treatment of ADs in this group of patients are discussed.

[A longitudinal study of pediatric-onset multiple sclerosis in the Voronezh region].

Objective: To study the clinical course, the rate of progression and the results of the disease modifying treatment (DMT) in pediatric-onset multiple sclerosis (POMS) patients in the Voronezh region.

Material And Methods: The clinical characteristics of the course of relapsing-remitting multiple sclerosis (MS) were analyzed among 51 POMS patients and 51 patients with the adult-onset MS (AOMS). The clinical course was assessed based on the Expanded Disability Status Scale (EDSS) score, the average annual frequency of exacerbations and the rate of disease progression before and during DMT.

[A case of a pathological variant of the PRRT2 gene in twins with paroxysmal kinesiogenic dyskinesia].

Paroxysmal dyskinesia is a clinically and etiologically polymorphic group of diseases, the main clinical manifestation of which is transient attacks of extrapyramidal movements, with different conditions of occurrence. Paroxysmal kinesigenic dyskinesia belongs to the group of primary dyskinesias, which also includes paroxysmal non-kinesigenic dyskinesia and exercise-induced paroxysmal dyskinesia. The most common cause of paroxysmal kinesiogenic dyskinesia is mutations in the PRRT2 gene; in cases of non-kinesiogenic dyskinesia, a mutation in the MR1 gene is detected.

[P.S. Babkin (To the 100th anniversary)].

There was the 100th anniversary of the birth of Peter Semenovich Babkin, a front-line soldier, famous neurologist, clinician, scientist and educator, Professor, Doctor of Medical Sciences, the founder of the theory of intrapartum fetal hibernation and maternal autoanalgesia.

[Improvement of the efficacy and safety of treatment of epilepsy using new forms of controlled release antiepileptic drugs].

The paper summarizes the results of the studies on the efficacy and safety of a new form of controlled release levetiracetam XR (Lev XR) compared to standard tablet immediate release form in treatment of resistant partial seizures. The authors present the data on the bioequivalence and absorption of LevXR related to the meal and therapeutic doses in the range between 1000 to 3000 mg/day. It has been concluded that LevXR has high efficacy and safety due to its stable plasma concentration during the day.